Chilton Capital Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,206 shares of the company’s stock after selling 4,589 shares during the period. Chilton Capital Management LLC’s holdings in Johnson & Johnson were worth $11,404,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the period. Landmark Financial Advisors LLC raised its position in Johnson & Johnson by 0.4% during the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the period. Premier Asset Management LLC raised its position in Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares during the period. Lbmc Investment Advisors LLC raised its position in Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after purchasing an additional 14 shares during the period. Finally, Halbert Hargrove Russell LLC raised its position in Johnson & Johnson by 0.4% during the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 65.89% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) traded up $0.58 during trading hours on Monday, reaching $140.59. The company had a trading volume of 5,101,300 shares, compared to its average volume of 5,868,289. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $144.35. The company has a market capitalization of $377,697.84, a PE ratio of 19.69, a P/E/G ratio of 2.86 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.39%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

JNJ has been the topic of a number of recent research reports. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday, October 19th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Citigroup began coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their target price for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Finally, Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $144.59.

COPYRIGHT VIOLATION NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/11/johnson-johnson-jnj-shares-sold-by-chilton-capital-management-llc.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.